Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SoloVir Electrokinetic Transdermal System: Phase II data

In the double-blind, placebo-controlled Phase II TPI-H-221 trial in about 260 patients with recurrent herpes

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE